The Pediatrics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pediatric partnering deals and agreements entered into by the worlds leading healthcare companies.
Arbor Pharmaceuticals LLC is allegedly exploring a potential acquisition and merger partner that could bring in more than $1 billion, according to people who are close to the situation.
By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.
Partnering trends for the top pharma and biotech companies reviewed with over 2,000 deals analyzed – including summary biopharma deal financials
Abbott Laboratories is a top pharmaceutical company based in Illinois, USA
Merck & Co is a top pharma company active in partnering, licensing and M&A in pharmaceuticals, consumer health and animal health
Lupin Ltd.is looking to aggressively grow its business in the U.S. and is scouting for M&A of pharmaceutical brands and manufacturers, and seeking regulatory approval to sell a wider range of niche generic drugs.
Written and published by partneringNEWS. By controlling the taste, bioavailability or timed release of drugs, Aptalis Pharmaceutical Technologies can help drug developers recoup the USD 30 billion lost to the industry each year because of patients not refilling—or never filling—their prescriptions. Controlling these factors also may improve compliance, lower dosage amounts, reduce side effects and more »
Sorry, your search returned no results.
The termination was received on July 8, 2009, effective immediately. All rights licensed to AstraZeneca in the agreement now revert to the company.
OPKO Health and Pfizer have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency
Xeltis has raised EURO 27 million (USD 34 million/CHF 32 million) in an oversubscribed Series B financing
FSC Therapeutics has entered into a transaction with Eisai Inc. to acquire exclusive U.S. marketing rights for AcipHex Sprinkle (rabeprazole sodium).
Lumena Pharmaceuticals has secured $45 million in Series B financing.
GlaxoSmithKline , a big pharma company, announced a new four year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services , for the provision of its inhalation anthrax treatment, raxibacumab, forming biopharma partners
Ultragenyx Pharmaceutical has entered into pharma deals with Kyowa Hakko Kirin, to develop and commercialize KRN23.
Pfizer,a big pharma company, signs pharmaceutical deals to provide additional doses of Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]), the company’s 13-valent pneumococcal conjugate vaccine, for use in infants and young children to help protect against pneumococcal disease1 in the world’s poorest countries under the terms of the Advance Market Commitment.